[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Li Q, Gao T, Jiao B, Qi X, Long HA, Qiao H, Wang L, Lv Y, Hu X, Liao W, Wang S, Li C: Long-term follow-up of in situ extramammary Paget's disease in Asian skin types IV/V treated with photodynamic therapy. Acta Derm Venereol; 2010 Mar;90(2):159-64
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of in situ extramammary Paget's disease in Asian skin types IV/V treated with photodynamic therapy.
  • Photodynamic therapy is a potentially advantageous treatment for non-melanoma skin cancers.
  • We evaluated the clinical response, recurrence and adverse events of photodynamic therapy for in situ extramammary Paget's disease in 14 male and 3 female Chinese patients with 21 lesions.
  • Each lesion was irradiated with 633 nm red light three times, 1 week apart, at a total dose of 339 J/cm2, followed by three assessments at 6, 12 and 24 months.
  • In conclusion, photodynamic therapy for extramammary Paget's disease is not recommended as the first option except for scrotal cases or lesions < 4 cm in diameter.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Asian Continental Ancestry Group. Carcinoma in Situ / drug therapy. Paget Disease, Extramammary / drug therapy. Penile Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Aged, 80 and over. Chi-Square Distribution. China / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Patient Satisfaction. Prospective Studies. Recurrence. Scrotum / pathology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169299.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


2. Badgwell C, Rosen T: Treatment of limited extent extramammary Paget's disease with 5 percent imiquimod cream. Dermatol Online J; 2006;12(1):22
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of limited extent extramammary Paget's disease with 5 percent imiquimod cream.
  • Extramammary Paget's disease (EMPD) is a rare neoplastic condition of apocrine gland-bearing skin, which may be associated with internal malignancy.
  • Although surgical excision is the generally accepted standard of care for EMPD, treatment with topical imiquimod 5 percent cream has reportedly been efficacious in clearing lesions.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Paget Disease, Extramammary / drug therapy. Paget Disease, Extramammary / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Thigh
  • [MeSH-minor] Administration, Topical. Aged. Drug Administration Schedule. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638390.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


3. Berman B, Perez OA, Zell D: Immunological strategies to fight skin cancer. Skin Therapy Lett; 2006 Jun;11(5):1-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological strategies to fight skin cancer.
  • Skin cancer is the most common human cancer, and is currently considered a global epidemic.
  • Recently, there has been a growing interest in immunomodulators, or up-regulators of the immune response, for the treatment and cure of various forms of skin cancer, including melanoma and nonmelanoma skin cancers, cutaneous T-cell lymphoma, Kaposi's sarcoma, cutaneous extramammary Paget's disease, and vulvar intraepithelial carcinoma neoplasia.
  • Strategies to augment the host's immune response against cancer cells and/or cancer cell antigenicity have been investigated, including recombinant cytokines, immunomodulators, dendritic cell immunization, tumor antigen vaccination, T-cell-based immunotherapy, and gene therapy.
  • Although the current standard of care for most of these cancers includes Mohs micrographic surgery, curettage, and cryo-, laser-, or radiotherapy, immunomodulators are becoming essential in the treatment of patients who are poor surgical candidates and/or require noninvasive therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunologic Factors / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aminoquinolines / therapeutic use. Humans. Interferons / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820869.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  • [Number-of-references] 45
  •  go-up   go-down


Advertisement
4. Ye JN, Rhew DC, Yip F, Edelstein L: Extramammary Paget's disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid: a case report. Cutis; 2006 Apr;77(4):245-50
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramammary Paget's disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid: a case report.
  • Extramammary Paget's disease (EMPD) is an uncommon skin neoplasm that usually affects the elderly population and occurs in the genital, anorectal, or axillary areas.
  • The recommended treatment of EMPD involves surgical excision, including Mohs micrographic surgery; however, surgery is associated with a high rate of recurrence.
  • There have been reports of successful treatment of recurrence with monochemotherapy involving topical imiquimod 5% cream.
  • To our knowledge, this is the first reported case of imiquimod combination therapy with 5-FU and retinoic acid for the treatment of recurrent EMPD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genital Neoplasms, Male / diagnosis. Genital Neoplasms, Male / drug therapy. Paget Disease, Extramammary / diagnosis. Paget Disease, Extramammary / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Aminoquinolines / administration & dosage. Diagnosis, Differential. Fluorouracil / administration & dosage. Humans. Male. Tretinoin / administration & dosage

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706242.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 5688UTC01R / Tretinoin; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 18
  •  go-up   go-down


5. Kim TH, Chang IH, Kim TH, Lee SY, Myung SC: Extramammary Paget's disease of scrotum treated with radiotherapy. Urology; 2009 Aug;74(2):474.e1-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramammary Paget's disease of scrotum treated with radiotherapy.
  • Extramammary Paget's disease (EMPD) of the scrotum is extremely rare.
  • EMPD must be differentiated from benign papulosquamous disease, squamous cell carcinoma and melanoma.
  • It can be managed by local excision and reconstruction with a skin graft or skin flap.
  • Radiation and topical chemotherapy have also been used as alternative treatment strategies and are effective for local control.
  • [MeSH-major] Genital Neoplasms, Male / radiotherapy. Paget Disease, Extramammary / radiotherapy. Scrotum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476986.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Takahagi S, Noda H, Kamegashira A, Madokoro N, Hori I, Shindo H, Mihara S, Hide M: Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy. J Dermatol; 2009 Aug;36(8):457-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy.
  • In the treatment of metastatic breast cancer, trastuzumab, a recombinant monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is effective when tumor cells overexpress HER2 protein.
  • Although some cases of extramammary Paget's disease (EMPD) also express HER2 protein, no case of EMPD has been reported to be treated with trastuzumab.
  • Although he was postoperatively treated with adjuvant chemotherapies, metastatic skin lesions appeared and spread over his left thigh, rapidly and widely.
  • The skin metastasis dramatically decreased during the regimen and a histopathological examination showed that most of HER2-positive tumor cells diminished.
  • Six months later, metastases were found in the central nervous system (CNS), but no other metastases were found in the skin, visceral organs or lymph nodes.
  • Trastuzumab and paclitaxel-combination with the assessment of central nervous system lesions should be considered as an option for the treatment of HER2-positive EMPD.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Paget Disease, Extramammary / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols. Central Nervous System / pathology. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / secondary. Genital Neoplasms, Male / drug therapy. Genital Neoplasms, Male / pathology. Genital Neoplasms, Male / surgery. Humans. Male. Skin / pathology. Trastuzumab

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691751.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Mirer E, El Sayed F, Ammoury A, Lamant L, Messer L, Bazex J: Treatment of mammary and extramammary Paget's skin disease with topical imiquimod. J Dermatolog Treat; 2006;17(3):167-71
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of mammary and extramammary Paget's skin disease with topical imiquimod.
  • BACKGROUND: Paget's disease is an uncommon epidermal cancer, affecting all skin regions wherever apocrine glands are present.
  • It is divided into extramammary (EMPD) and mammary Paget's disease (MPD).
  • The diagnosis is confirmed by skin biopsy and the treatment depends on characteristics of the underlying cancer.
  • Surgery is the first-line treatment.
  • Imiquimod, a topical immunomodulator, approved its efficiency in several skin neoplasms and has been shown as a safe treatment for EMPD.
  • However, it has never been reported for the treatment of MPD.
  • CONCLUSION: This non-surgical method may be considered as a primary treatment when Paget's disease is not associated with an underlying malignancy.
  • The good prognosis with a long-term survival, the anatomic localization and the poor general condition of elderly people may favor imiquimod as an alternative treatment.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Paget Disease, Extramammary / drug therapy. Paget's Disease, Mammary / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Groin. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Dermatolog Treat. 2007;18(3):191-2 [17538811.001]
  • (PMID = 16854759.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


8. Mochitomi Y, Sakamoto R, Gushi A, Hashiguchi T, Mera K, Matsushita S, Nishi M, Kanzaki T, Kanekura T: Extramammary Paget's disease/carcinoma successfully treated with a combination chemotherapy: report of two cases. J Dermatol; 2005 Aug;32(8):632-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramammary Paget's disease/carcinoma successfully treated with a combination chemotherapy: report of two cases.
  • We have treated two patients with extramammary Paget's disease/carcinoma (EMPD/C), a 62-year-old woman and a 78-year-old man.
  • After surgery, they underwent 5 courses of systemic combination chemotherapy at 4-week intervals to residual or recurrent lymph node metastasis.
  • The affected lymph nodes in both patients subsided in response to the chemotherapy.
  • Positron emission tomography (PET) scans confirmed the complete remission of lymph node metastasis in Case 1.
  • In Case 2, they were reduced by more than 90% on computed tomography (CT) scans.
  • Adverse effects included leukocytopenia, vomiting, hypesthesia, and constipation, all of which disappeared after the completion of chemotherapy.
  • While surgery with wide local excision is the treatment of choice in patients with EMPD/C, there is currently no standardized treatment for advanced cases with metastasis.
  • We describe two patients with EMPD/C whose metastatic lesions responded well to this combination of chemotherapy.
  • [MeSH-major] Paget Disease, Extramammary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Groin. Humans. Lymphatic Metastasis. Male. Middle Aged. Perineum. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334862.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Tulchinsky H, Zmora O, Brazowski E, Goldman G, Rabau M: Extramammary Paget's disease of the perianal region. Colorectal Dis; 2004 May;6(3):206-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramammary Paget's disease of the perianal region.
  • OBJECTIVE: Perianal Paget's disease (PPD) is a rare entity.
  • The standard treatment for either in situ or invasive extra mammary Paget's disease (EMPD) is surgical excision.
  • The aim of this article is to review our experience with PPD and question the currently preferred treatment approaches in light of its histopathology and therapeutic outcome.
  • PATIENTS AND METHODS: A chart review of our patients with PPD from 1996 to 2002 was carried out to determine their outcome after treatment.
  • RESULTS: Five patients with in situ disease (four females, median age 68 years) were diagnosed as having PPD.
  • A complete surgical excision was attempted in 4 patients and the fifth was treated by photodynamic therapy.
  • At present, all patients are alive, two are free of disease, one has persistent disease and two have local recurrence.
  • CONCLUSION: Considering the significant rate of recurrence even after wide local excision, the extent of surgery needed and the good prognosis with long-term survival, we question whether nonsurgical modalities should be considered in place of surgery as primary treatment for noninvasive PPD, with radical surgery being reserved for failures or invasive disease.
  • [MeSH-major] Paget Disease, Extramammary / drug therapy. Paget Disease, Extramammary / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anal Canal. Antineoplastic Agents / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15109389.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents
  •  go-up   go-down


10. Enjoji M, Noguchi K, Watanabe H, Yoshida Y, Kotoh K, Nakashima M, Watanabe T, Nakamuta M, Nawata H: A novel tumour marker RCAS1 in a case of extramammary Paget's disease. Clin Exp Dermatol; 2003 Mar;28(2):211-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel tumour marker RCAS1 in a case of extramammary Paget's disease.
  • A 66-year-old male, whose primary skin lesion in extramammary Paget's disease had been surgically resected 4 years previously, was hospitalized with liver metastases.
  • Hepatic arterial infusion chemotherapy was carried out and the tumours clearly reduced in size.
  • Serum levels of some common tumour markers were not elevated, even prior to therapy.
  • The patient's serum RCAS1 level was elevated (22.0 U/mL) before therapy and fell during (10.5 U/mL) and after (5.0 U/mL) therapy.
  • Therefore, serum RCAS1 levels may be valuable as a potential biomarker for monitoring therapeutic efficacy against Paget's disease.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Genital Neoplasms, Male / immunology. Liver Neoplasms / immunology. Paget Disease, Extramammary / immunology. Scrotum. Skin Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12653716.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / EBAG9 protein, human
  •  go-up   go-down


11. Tsuji M, Nakai N, Ueda E, Takenaka H, Katoh N, Kishimoto S: Double cancer of plantar malignant melanoma and vulvar extramammary Paget's disease. J Dermatol; 2010 May;37(5):484-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double cancer of plantar malignant melanoma and vulvar extramammary Paget's disease.
  • Histopathological analysis of the vulvar lesion biopsy sample indicated extramammary Paget's disease (EMPD).
  • There was no evidence of metastasis in the computed tomography (CT) and (18)F-fluorodeoxyglucose positron emission tomography scans.
  • Melanoma cells were identified in the sentinel lymph nodes, and left radical lymph node dissection was performed after a course of neoadjuvant chemotherapy.
  • Thereafter, we administrated four courses of chemotherapy, and 8 months after the operation, there was no evidence of recurrence or metastatic lesions.
  • [MeSH-major] Foot Diseases / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Paget Disease, Extramammary / pathology. Skin Neoplasms / pathology. Vulvar Neoplasms / pathology


12. Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Mao HR: Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease. Br J Dermatol; 2009 Sep;161(3):577-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease.
  • BACKGROUND: Metastatic penoscrotal extramammary Paget's disease (EMPD) has seldom been reported in the literature.
  • OBJECTIVES: To improve the knowledge of the clinicopathological characteristics, management and outcome in patients with this disease.
  • METHODS: The medical records and pathological slides of 10 patients with metastatic EMPD and 33 patients with nonmetastatic disease were reviewed.
  • Immunohistochemical staining for epithelial cadherin (E-cadherin) was performed in the primary skin disease.
  • All the 10 patients received 5-fluorouracil- or docetaxel-based chemotherapy.
  • In three patients, (18)F-fluorodeoxyglucose positron emission tomography (PET)-computed tomography (CT) scans revealed occult lymph node metastases which were overlooked at conventional CT examinations.
  • Two patients had complete response to the chemotherapy, three had partial response and five had progressive disease.
  • In those patients with significantly elevated CEA level, the value of CEA paralleled the disease course.
  • 5-Fluorouracil- or docetaxel based-chemotherapy was effective in some patients.
  • Serum CEA level can be a useful biomarker for monitoring disease course.
  • [MeSH-major] Genital Neoplasms, Male / pathology. Paget Disease, Extramammary / pathology. Penile Neoplasms / pathology. Scrotum / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Cadherins / analysis. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Neoplasm Invasiveness. Survival Analysis. Taxoids / therapeutic use

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438449.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Taxoids; 15H5577CQD / docetaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Ho SA, Aw DC: Extramammary Paget's disease treated with topical imiquimod 5% cream. Dermatol Ther; 2010 Jul-Aug;23(4):423-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramammary Paget's disease treated with topical imiquimod 5% cream.
  • Extramammary Paget's disease (EMPD) is a rare cutaneous, intraepithelial adenocarcinoma usually found in the apocrine gland bearing areas.
  • Of late, topical imiquimod 5% cream has come into use as another treatment option.
  • We present two cases of EMPD in Asian skin treated successfully with topical imiquimod 5% cream.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Paget Disease, Extramammary / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Asian Continental Ancestry Group. Female. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666831.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


14. Takahashi A, Yamamoto A: [Diagnosis and treatment of extramammary Paget's disease]. Gan To Kagaku Ryoho; 2004 Mar;31(3):356-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of extramammary Paget's disease].
  • Extramammary Paget's disease is a malignant tumor with the characteristic bright large atypical cells called Paget's cells, which proliferate within an intraepidermal lesion outside the breast.
  • Extramammary Paget's disease is commonly an intraepidermal neoplasm.
  • However, if the tumor cells infiltrate into the dermis and form a clinically manifest nodule, it becomes an invasive carcinoma that can be classified as adnexal adenocarcinoma of the skin.
  • Surgery with wide local excision is the first choice of treatment, and the prognosis is comparatively favorable in the early stages.
  • However, when tumor cells infiltrate into the dermis and advance to Paget's carcinoma, it is referred to as adenocarcinoma of the skin and has a poor prognosis.
  • We report an effective treatment of extramammary Paget's disease in advanced stages' including our case.
  • No standard treatment with a significant effect has yet been established.
  • There are few reports of cases responsive to chemotherapy, and treatment in advanced stages is extremely difficult at present.
  • [MeSH-major] Paget Disease, Extramammary. Skin Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Diagnosis, Differential. Genitalia, Male. Humans. Male. Perineum. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045940.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


15. Ng LG, Yip SK, Tan PH: Extramammary Paget's disease of scrotum. Urology; 2001 Jul;58(1):105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramammary Paget's disease of scrotum.
  • We describe 4 cases of extramammary Paget's disease of the scrotum with underlying invasive carcinoma from 1997 to 1999.
  • The delay in diagnosis was significant (mean 1 year).
  • The diagnosis was made by skin biopsy in all patients.
  • The mainstay of treatment is wide surgical excision, but positive margins remain a major problem.
  • Other modes of treatment have been advocated but the efficacy for invasive disease is low.
  • The key to successful control of the disease is therefore a high index of suspicion and early diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Genital Neoplasms, Male / pathology. Neoplasms, Multiple Primary / pathology. Paget Disease, Extramammary / pathology. Scrotum / pathology
  • [MeSH-minor] Aged. Biopsy. Carcinoma / pathology. Humans. Inguinal Canal. Lymphatic Metastasis. Male. Middle Aged. Psoriasis / complications. Psoriasis / drug therapy. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11445493.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Oguchi S, Kaneko M, Uhara H, Saida T: Docetaxel induced durable response in advanced extramammary Paget's disease: a case report. J Dermatol; 2002 Jan;29(1):33-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel induced durable response in advanced extramammary Paget's disease: a case report.
  • Skin biopsy confirmed the diagnosis of extramammary Paget's disease, and a CT scan revealed multiple metastases to the lymph nodes along the iliac artery and aorta.
  • The patient underwent combination chemotherapy with mitomycin C, epirubicin, vincristine, cisplatin, and 5-fluorouracil.
  • After two courses, the lymph node metastases decreased by 75% compared to the pre-treatment size, and the effect was judged a partial response.
  • Docetaxel may be an effective drug for patients with advanced extramammary Paget's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Paget Disease, Extramammary / drug therapy. Skin Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Epirubicin / administration & dosage. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Mitomycin / administration & dosage. Scrotum. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11837572.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; 5J49Q6B70F / Vincristine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Del Castillo LF, Garcia C, Schoendorff C, Garcia JF, Torres LM, Garcia Almagro D: Spontaneous apparent clinical resolution with histologic persistence of a case of extramammary Paget's disease: response to topical 5-fluorouracil. Cutis; 2000 May;65(5):331-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous apparent clinical resolution with histologic persistence of a case of extramammary Paget's disease: response to topical 5-fluorouracil.
  • An 86-year-old woman presented with a 3-year history of an erythematous axillary lesion, which was histologically confirmed to be extramammary Paget's disease (EMPD) confined to the epidermis and adnexa.
  • Surprisingly, spontaneous clinical regression occurred in the lesion, but Paget's cells persisted within the epidermis and adnexa on histologic examination.
  • One year of intermittent topical chemotherapy with 5-fluorouracil resulted in ulcers that were interpreted as EMPD and completely excised.
  • Histologic examination showed a complete absence of Paget's cells.
  • We emphasize that topical 5-fluorouracil cannot be considered a safe treatment modality for EMPD, but it may be useful in certain cases in which the extent of the lesions, or the general condition of the patient, advise against surgery or radiotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Paget Disease, Extramammary / drug therapy. Paget Disease, Extramammary / physiopathology. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cutis. 2000 Dec;66(6):454-5 [11138364.001]
  • (PMID = 10826098.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Zampogna JC, Flowers FP, Roth WI, Hassenein AM: Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol; 2002 Oct;47(4 Suppl):S229-35
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports.
  • We present two cases of primary limited cutaneous perineal and genital extramammary Paget's disease (EMPD) that were successfully treated with imiquimod 5% cream.
  • Treatment-associated morbidity is minimal compared with more invasive therapies, and self-application by the patient improves convenience and appeal.
  • Imiquimod may offer a minimally invasive and promising therapeutic option for the treatment of limited cutaneous EMPD.
  • The diagnosis and management of EMPD and the current literature regarding imiquimod therapy are reviewed.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Interferon Inducers / administration & dosage. Paget Disease, Extramammary / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Perineum. Scrotum

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12271284.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Interferon Inducers; P1QW714R7M / imiquimod
  • [Number-of-references] 25
  •  go-up   go-down


19. Housel JP, Izikson L, Zeitouni NC: Noninvasive extramammary Paget's disease treated with photodynamic therapy: case series from the Roswell Park Cancer Institute. Dermatol Surg; 2010 Nov;36(11):1718-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive extramammary Paget's disease treated with photodynamic therapy: case series from the Roswell Park Cancer Institute.
  • BACKGROUND: Extramammary Paget's disease (EMPD) is a rare low-grade cutaneous malignancy that affects apocrine gland-bearing areas and most commonly occurs on the perineal skin.
  • Photodynamic therapy (PDT) may represent a useful treatment option for extensive, noninvasive EMPD, alone or as part of multimodal therapy.
  • RESULTS: Seven of nine lesions (78%) treated with PDT using intravenous porfimer sodium showed a complete response (CR) and were disease free at 12 to 96 months.
  • Eight of 16 lesions (50%) treated with PDT using topical ALA showed a CR, and 38% were disease free at 9 to 88 months.
  • None of the treated patients developed any serious cosmetic or functional impairments, such as loss of sphincter control or dysesthesias.
  • CONCLUSION: PDT with intravenous porfimer sodium or topical ALA and argon laser may represent a useful, surgery-sparing therapeutic option for management of noninvasive EMPD in selected patients.
  • [MeSH-major] Paget Disease, Extramammary / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 by the American Society for Dermatologic Surgery, Inc.
  • [CommentIn] Dermatol Surg. 2010 Nov;36(11):1725 [20979337.001]
  • (PMID = 20849546.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


20. Sendagorta E, Herranz P, Feito M, Ramírez P, Floristán U, Feltes R, Benito DM, Casado M: Successful treatment of three cases of primary extramammary Paget's disease of the vulva with Imiquimod--proposal of a therapeutic schedule. J Eur Acad Dermatol Venereol; 2010 Apr;24(4):490-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of three cases of primary extramammary Paget's disease of the vulva with Imiquimod--proposal of a therapeutic schedule.
  • BACKGROUND/AIM: Extramammary Paget's disease (EMPD) is an intraepidermal adenocarcinoma of apocrine gland-bearing skin.
  • Although surgery remains the mainstay of treatment, loss of tissue function and high recurrence rates have been reported.
  • Recently, topical Imiquimod has been shown as a safe and effective treatment option for extramammary Paget's disease.
  • RESULTS: Complete clinical and histological remission of the disease was achieved in the three patients.
  • CONCLUSION: Based on our results, we consider that Imiquimod cream is a safe and effective therapeutic option for the treatment of vulvar EMPD.
  • These promising results warrant further studies to determine the real efficacy and safety of Imiquimod 5% cream for the treatment of this uncommon disease.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Paget Disease, Extramammary / drug therapy. Skin Neoplasms / drug therapy. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840203.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


21. Olazarán-Medrano Z, Treviño-González JJ, Salas-Alanís JC, Lemus-Arias JA: [Treatment with imiquimod and surgical excision of a patient with extramammary Paget's disease. Case report]. Rev Med Inst Mex Seguro Soc; 2010 Jan-Feb;48(1):83-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment with imiquimod and surgical excision of a patient with extramammary Paget's disease. Case report].
  • [Transliterated title] Tratamiento con imiquimod y escisión quirúrgica en un paciente con enfermedad extramamaria de Paget. Caso clínico.
  • Extramammary Paget's disease (EMPD) is a less common cutaneous type of cancer.
  • It presents as erythematous plaques most frequently located in the genital region, perianal skin, and other cutaneous sites rich in apocrine glands, but it also may originate from keratinocytic stem cells.
  • Recently, imiquimod has been used for the management of primary or relapsing extramammary Paget's disease.
  • Complete healing, without recurrence, of extramammary Paget's disease in patients whom were treated topically with 5 % imiquimod cream was observed.
  • We report a 78 year-old patient with scrotal and perianal extramammary Paget's disease treated with imiquimod cream in both lesions and subsequently with surgical excision in scrotum for the management of relapsing disease.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / surgery. Genital Neoplasms, Male / drug therapy. Genital Neoplasms, Male / surgery. Paget Disease, Extramammary / drug therapy. Paget Disease, Extramammary / surgery. Scrotum
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20696113.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


22. Preti M, Micheletti L, Ghiringhello B, Privitera S, Condello V, Chieppa P, Massobrio M: [Vulvar Paget's disease. Clinico-pathologic review of the literature]. Minerva Ginecol; 2000 May;52(5):203-11
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vulvar Paget's disease. Clinico-pathologic review of the literature].
  • [Transliterated title] La malattia di Paget vulvare. Revisione clinico-patologica della letteratura.
  • In 1986 the International Society For the Study of Vulvar Disease classified vulvar Paget's disease (VPD) as a non-squamous intraepithelial lesion of the vulva.
  • Paget's cells could be instead easily identified at histological examination and with histochemical reactions.
  • Therapy for intraepithelial VPD is wide and deep surgical resection comprising all the skin appendages.
  • The role of chemotherapy and radiotherapy in the multimodal approach to extensive or recurring VPD is still controversial.
  • [MeSH-major] Paget Disease, Extramammary / pathology. Vulvar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048477.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] ITALY
  • [Number-of-references] 69
  •  go-up   go-down


23. Vereecken P, Awada A, Ghanem G, Marques da Costa C, Larsimont D, Simoens C, Mendes da Costa P, Hendlisz A: A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery. Med Sci Monit; 2007 Jun;13(6):CS75-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery.
  • BACKGROUND: Extramammary Paget's disease (EMPD) is a rare skin disease which can be limited to the epidermis and can sometimes also be associated with underlying carcinomas.
  • Surgery is the cornerstone treatment.
  • Three months of daily application of topical imiquimod was prescribed as an alternative treatment.
  • CONCLUSIONS: This successful treatment of a perianal-located EMPD by topical imiquimod warrants further investigations.
  • [MeSH-major] Aminoquinolines / administration & dosage. Aminoquinolines / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Paget Disease, Extramammary / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534239.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


24. Watanabe Y, Hoshiai H, Ueda H, Nakai H, Obata K, Noda K: Low-dose mitomycin C, etoposide, and cisplatin for invasive vulvar Paget's disease. Int J Gynecol Cancer; 2002 May-Jun;12(3):304-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose mitomycin C, etoposide, and cisplatin for invasive vulvar Paget's disease.
  • We report the effect of low-dose mitomycin C, etoposide, and cisplatin (low-dose MEP) therapy for three patients with invasive vulvar Paget's disease (invasive VPD) who declined radical vulvectomy and skin grafting.
  • All patients have no sign of recurrence for 10 months after chemotherapy.
  • Our present results suggest that low-dose MEP is an effective and safe chemotherapy for invasive VPD and low-dose MEP may significantly improve postoperative quality of life in patients with invasive VPD by avoiding extensive vulvar resection and skin grafting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Paget Disease, Extramammary / drug therapy. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060453.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Berman B, Spencer J, Villa A, Poochareon V, Elgart G: Successful treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream. Clin Exp Dermatol; 2003 Nov;28 Suppl 1:36-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream.
  • Extramammary Paget's disease (EMPD) of the skin is an uncommon malignancy involving the epidermis, which sometimes extends into the dermis.
  • Current treatments for EMPD are surgical excision, Mohs' micrographic surgery or laser ablation.
  • During the initial weeks of therapy, he experienced moderate erythema.
  • Imiquimod treatment resulted in clinical and histological eradication of EMPD, with no recurrence observed during 6 months of follow-up.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Genital Neoplasms, Male / drug therapy. Paget Disease, Extramammary / drug therapy. Scrotum. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Biopsy / methods. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616812.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


26. Runfola MA, Weber TK, Rodriguez-Bigas MA, Dougherty TJ, Petrelli NJ: Photodynamic therapy for residual neoplasms of the perianal skin. Dis Colon Rectum; 2000 Apr;43(4):499-502
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for residual neoplasms of the perianal skin.
  • PURPOSE: The aim of this study was to evaluate the efficacy of photodynamic therapy in the management of residual neoplasms of the perianal skin.
  • Five patients with pathologic confirmation of residual perianal neoplasms were treated with photodynamic therapy.
  • Pathology consisted of Bowen's disease in two patients, squamous-cell carcinoma in two patients, and extramammary Paget's disease in one patient.
  • Four patients received one photodynamic therapy treatment and one patient received two treatments three months apart.
  • RESULTS: Treatment was followed by immediate perianal erythema, subsequent blister formation in 36 to 48 hours, and sloughing of the treated area in 72 hours.
  • One recurrence was in a patient four years after treatment for Paget's disease, and the other was in a patient nine months after treatment for Bowen's disease.
  • Treatment-related toxicities included significant perianal pain in four patients, controlled with analgesia management.
  • CONCLUSIONS: Photodynamic therapy can successfully be used after wide local excision for residual neoplasms of the perianal skin.
  • Treatment can be rendered with acceptable morbidity.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / drug therapy. Bowen's Disease / drug therapy. Carcinoma, Squamous Cell / drug therapy. Paget Disease, Extramammary / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10789745.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Woodmansee C, Pillow J, Skinner RB Jr: The role of topical immune response modifiers in skin cancer. Drugs; 2006;66(13):1657-64
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of topical immune response modifiers in skin cancer.
  • Imiquimod is approved for the treatment of actinic keratoses, superficial basal cell carcinomas and warts; it has also been documented to successfully treat other forms of skin cancer such as squamous cell carcinoma in situ, melanoma and extramammary Paget's disease.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aminoquinolines / administration & dosage. Aminoquinolines / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cytokines / metabolism. Humans. Imidazoles / administration & dosage. Imidazoles / therapeutic use. Models, Biological. Toll-Like Receptors / physiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 May;122(5):1266-76 [15140231.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:59-61 [14616354.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Dec;47(12):3846-52 [14638493.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10 ):1027-34 [12974699.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:66-70 [14616356.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4):497-501 [12271290.001]
  • [Cites] Dermatol Surg. 2004 Aug;30(8):1101-12 [15274700.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):510-4 [15837872.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S229-35 [12271284.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4):571-7 [12271303.001]
  • [Cites] J Am Acad Dermatol. 2000 Sep;43(3):555-6 [10954675.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):945-7 [12873904.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Dermatol Surg. 2005 Jun;31(6):659-64 [15996416.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] J Drugs Dermatol. 2003 Jan;2(1):73-6 [12852386.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S225-8 [12271283.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):273-6 [12622616.001]
  • [Cites] Arch Dermatol. 2001 Jan;137(1):14-6 [11176654.001]
  • [Cites] Arch Dermatol. 2004 Dec;140(12 ):1542 [15611446.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] Br J Dermatol. 2001 Dec;145(6):1022-3 [11899127.001]
  • [Cites] J Am Acad Dermatol. 2002 Apr;46(4):545-8 [11907505.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):843-5 [11069469.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • (PMID = 16978032.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Imidazoles; 0 / Toll-Like Receptors; P1QW714R7M / imiquimod; V3DMU7PVXF / resiquimod
  • [Number-of-references] 35
  •  go-up   go-down


28. Akita Y, Kozaki K, Nakagawa A, Saito T, Ito S, Tamada Y, Fujiwara S, Nishikawa N, Uchida K, Yoshikawa K, Noguchi T, Miyaishi O, Shimozato K, Saga S, Matsumoto Y: Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br J Dermatol; 2004 Aug;151(2):472-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
  • BACKGROUND: Anti-cancer effects of cyclooxygenase (COX)-2 inhibitors have been reported, but not fully investigated in skin and oral diseases.
  • 5-aminolaevulinic acid (ALA)-based photodynamic therapy (PDT) for treating those patients with skin and oral lesions is a highly sophisticated procedure, but the incidence of disease recurrence after treatment is rather significant.
  • OBJECTIVE: To confirm that COX-2 could be a molecular target in adjunctive therapy to ALA-based PDT, we investigated (i) COX-2 expression in various skin and oral diseases, and (ii) the inhibitory effects on cellular growth of COX-2 selective inhibitor (nimesulide), ALA-based PDT and their combination on human oral squamous cell carcinoma (SCC) cell lines.
  • METHODS: A total of 129 biopsy samples from the skin and oral mucosal lesions were tested immunohistochemically for COX-2 expression.
  • RESULTS: Among the skin diseases, a considerable number of COX-2 high expressers were found in actinic keratosis (15 of 25, 60%), Bowen's disease (13 of 17, 76%) and extramammary Paget's disease (15 of 15, 100%).
  • CONCLUSIONS: Our study strongly suggests that COX-2 can be one of the molecular targets in treating various skin and oral diseases.
  • The results from our in vitro experiments also prompt us to develop a new protocol with a combination of COX-2 selective inhibitor and ALA-based PDT for more effective treatment of those diseases.
  • [MeSH-major] Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / antagonists & inhibitors. Mouth Diseases / drug therapy. Photochemotherapy / methods. Skin Diseases / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Aminolevulinic Acid / therapeutic use. Bowen's Disease / drug therapy. Bowen's Disease / enzymology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Cell Division / drug effects. Cell Line, Tumor. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Drug Synergism. Drug Therapy, Combination. Humans. Immunohistochemistry / methods. Keratosis / drug therapy. Keratosis / enzymology. Membrane Proteins. Mouth Mucosa / enzymology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / enzymology. Paget Disease, Extramammary / drug therapy. Paget Disease, Extramammary / enzymology. Photosensitizing Agents / therapeutic use. Prostaglandin-Endoperoxide Synthases / analysis

  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15327557.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Photosensitizing Agents; 0 / Sulfonamides; 88755TAZ87 / Aminolevulinic Acid; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; V4TKW1454M / nimesulide
  •  go-up   go-down


29. Villa AM, Berman B: Immunomodulators for skin cancer. J Drugs Dermatol; 2004 Sep-Oct;3(5):533-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunomodulators for skin cancer.
  • Therapeutic interventions to augment tumor antigenicity or increase the host's immune response against cancer cells include recombinant cytokines, immune modulators, vaccination with tumor antigens, T cell-based immunotherapy, and gene therapy.
  • We describe the current role of the immunomodulators (up-regulators of the immune response) in the therapy of skin cancer (non melanoma skin cancer, melanoma, lymphoma, Kaposi sarcoma, and extramammary Paget's disease).
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Bowen's Disease / drug therapy. Immunologic Factors / therapeutic use. Interferons / therapeutic use. Lymphoma / drug therapy. Melanoma / drug therapy. Paget Disease, Extramammary / drug therapy. Sarcoma, Kaposi / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15552605.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  • [Number-of-references] 67
  •  go-up   go-down


30. Zhang ZL, Meng XW, Xing XP, Wang O, Xia WB, Li M, Jiang Y, Fu Y, Zhou XY: [Prospective study of pamidronate disodium in treatment of Paget's disease of bone]. Zhonghua Yi Xue Za Zhi; 2003 Oct 10;83(19):1653-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prospective study of pamidronate disodium in treatment of Paget's disease of bone].
  • OBJECTIVE: To determine the efficacy of pamidronate disodium (pamidronate) in treatment of Paget's disease of bone.
  • METHODS: Intravenous drip of pamidronate was given at the dose of 30 - 60 mg per day for 2 - 3 weeks with a total dosage of 90 - 270 (168 +/- 84) mg to 5 patients with Paget's disease of bone, 2 males and 3 females, aged 27 - 74 (61 on average) with the course of disease of 4 - 48 years (24 years on average), all of them having multiple bone lesions, 2 being in grade 4 of pain assessment and bedridden and 3 being in grade 3 with impaired mobility.
  • Pain assessment, biochemical markers of bone turnover, including serum alkaline phosphatase (ALP), carboxy-terminal propeptide of type I collagen (PICP), carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) and urinary hydroxyproline (HOP), and side effects of pamidronate were observed before treatment, by the end of treatment, and 4, 12, 24, and 48 weeks after treatment.
  • RESULTS: The Pagetic bone pain was significantly reduced by the end of treatment in all patients.
  • The mobility was markedly improved without bone pain 12 weeks after treatment and relief of pain lasted for 1 year in all patients.
  • Serum ALP, PICP, ICTP and urinary HOP concentrations were significant decrease by the end of treatment.
  • Moreover, the mean percentage decreases for above biochemical markers at 12 and 24 weeks after treatment were 50% or over.
  • The values of serum ALP, PICP, ICTP and urinary HOP decreased from 398 u/L (median), 818 ng/L (median), (29 +/- 14) ng/L and (71 +/- 16) mg/24 h urine respectively to 159 u/L, 129 ng/L, (12 +/- 4) ng/L and (34 +/- 7) mg/24 h urine respectively 48 weeks after treatment (all P < 0.05).
  • Side effects, including a transient increase in body temperature, skin eruption and pruritus, and a transient increase of serum aspartate aminotransferase concentration, were negligible.
  • CONCLUSION: Intravenous infusion of pamidronate is effective on Paget's disease of bone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Diphosphonates / therapeutic use. Paget Disease, Extramammary / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14642096.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  •  go-up   go-down


31. Gupta AK, Cherman AM, Tyring SK: Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg; 2004 Sep-Oct;8(5):338-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Imiquimod is a topical immunomodulator that is indicated for the treatment of external genital and perianal warts.
  • This drug has been recently approved for the treatment of actinic keratoses and superficial basal cell carcinoma.
  • There is a growing body of evidence for its effectiveness in treating a variety of other skin conditions.
  • OBJECTIVE: This review examines the role of imiquimod 5% cream in the treatment of skin diseases such as actinic keratoses, basal cell carcinoma, Bowen's disease, lentigo maligna, and extramammary Paget's disease.
  • Side effects are generally well tolerated with local skin reactions reported most frequently.
  • CONCLUSION: Imiquimod has been shown to be a safe and effective treatment for a variety of skin conditions.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Skin Diseases / drug therapy
  • [MeSH-minor] Administration, Topical. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Clinical Trials, Phase III as Topic. Condylomata Acuminata / drug therapy. Humans. Hutchinson's Melanotic Freckle / drug therapy. Keratosis / drug therapy. Models, Immunological. Ointments. Paget Disease, Extramammary / drug therapy. Randomized Controlled Trials as Topic. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868314.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Ointments; P1QW714R7M / imiquimod
  • [Number-of-references] 112
  •  go-up   go-down


32. Berman B, Poochareon VN, Villa AM: Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Therapy Lett; 2002 Nov;7(9):1-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imiquimod is the first of a new class of drugs to emerge in the treatment of various dermatologic disorders.
  • It is currently approved for the treatment of external genital and perianal warts, but has also been found to be an effective treatment for a host of other virus-associated dermatologic lesions, including common and flat warts, molluscum contagiosum and herpes simples 2.
  • Oncological lesions showing improvement with the use of imiquimod include basal cell carcinoma, actinic keratosis, squamous cell carcinoma in situ, malignant melanoma, cutaneous T-cell lymphoma, and cutaneous extramammary Paget's disease.
  • This extensive array of disorders treated successfully with imiquimod warrants further study of this novel and valuable drug.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Skin Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12548325.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  • [Number-of-references] 53
  •  go-up   go-down


33. Dias Coelho J, Vale E, Viana I, Martins O: Treatment of primary extramammary Paget's disease of the perineum with topical imiquimod 5% cream. Eur J Dermatol; 2010 Jul-Aug;20(4):532-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary extramammary Paget's disease of the perineum with topical imiquimod 5% cream.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Paget Disease, Extramammary / drug therapy. Perineum. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20566431.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


34. Misery L: Treatment of genital Paget's skin disease with topical imiquimod: severe adverse events. J Dermatolog Treat; 2007;18(3):191-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of genital Paget's skin disease with topical imiquimod: severe adverse events.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Drug Hypersensitivity / diagnosis. Genital Neoplasms, Female / drug therapy. Paget Disease, Extramammary / drug therapy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Dermatolog Treat. 2006;17(3):167-71 [16854759.001]
  • (PMID = 17538811.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


35. Yeh MH, Hu SL: Treatment of double ectopic extramammary Paget's disease of bilateral chest with imiquimod 5% cream. J Eur Acad Dermatol Venereol; 2007 Aug;21(7):997-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of double ectopic extramammary Paget's disease of bilateral chest with imiquimod 5% cream.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Paget Disease, Extramammary / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659025.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down






Advertisement